JP2017521469A5 - - Google Patents

Download PDF

Info

Publication number
JP2017521469A5
JP2017521469A5 JP2017504062A JP2017504062A JP2017521469A5 JP 2017521469 A5 JP2017521469 A5 JP 2017521469A5 JP 2017504062 A JP2017504062 A JP 2017504062A JP 2017504062 A JP2017504062 A JP 2017504062A JP 2017521469 A5 JP2017521469 A5 JP 2017521469A5
Authority
JP
Japan
Prior art keywords
weight
quinolin
imidazo
ylmethyl
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017504062A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017521469A (ja
JP6770946B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/055561 external-priority patent/WO2016012963A1/en
Publication of JP2017521469A publication Critical patent/JP2017521469A/ja
Publication of JP2017521469A5 publication Critical patent/JP2017521469A5/ja
Application granted granted Critical
Publication of JP6770946B2 publication Critical patent/JP6770946B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017504062A 2014-07-25 2015-07-22 2−フルオロ−n−メチル−4−[7−(キノリン−6−イルメチル)イミダゾ[1,2−b][1,2,4]トリアジン−2−イル]ベンズアミドの錠剤 Active JP6770946B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462028865P 2014-07-25 2014-07-25
US62/028,865 2014-07-25
PCT/IB2015/055561 WO2016012963A1 (en) 2014-07-25 2015-07-22 Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020058164A Division JP7002587B2 (ja) 2014-07-25 2020-03-27 2-フルオロ-n-メチル-4-[7-(キノリン-6-イルメチル)イミダゾ[1,2-b][1,2,4]トリアジン-2-イル]ベンズアミドの錠剤

Publications (3)

Publication Number Publication Date
JP2017521469A JP2017521469A (ja) 2017-08-03
JP2017521469A5 true JP2017521469A5 (cg-RX-API-DMAC7.html) 2018-08-30
JP6770946B2 JP6770946B2 (ja) 2020-10-21

Family

ID=53762251

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017504062A Active JP6770946B2 (ja) 2014-07-25 2015-07-22 2−フルオロ−n−メチル−4−[7−(キノリン−6−イルメチル)イミダゾ[1,2−b][1,2,4]トリアジン−2−イル]ベンズアミドの錠剤
JP2020058164A Active JP7002587B2 (ja) 2014-07-25 2020-03-27 2-フルオロ-n-メチル-4-[7-(キノリン-6-イルメチル)イミダゾ[1,2-b][1,2,4]トリアジン-2-イル]ベンズアミドの錠剤
JP2021211526A Pending JP2022046659A (ja) 2014-07-25 2021-12-24 2-フルオロ-n-メチル-4-[7-(キノリン-6-イルメチル)イミダゾ[1,2-b][1,2,4]トリアジン-2-イル]ベンズアミドの錠剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020058164A Active JP7002587B2 (ja) 2014-07-25 2020-03-27 2-フルオロ-n-メチル-4-[7-(キノリン-6-イルメチル)イミダゾ[1,2-b][1,2,4]トリアジン-2-イル]ベンズアミドの錠剤
JP2021211526A Pending JP2022046659A (ja) 2014-07-25 2021-12-24 2-フルオロ-n-メチル-4-[7-(キノリン-6-イルメチル)イミダゾ[1,2-b][1,2,4]トリアジン-2-イル]ベンズアミドの錠剤

Country Status (31)

Country Link
US (5) US10085993B2 (cg-RX-API-DMAC7.html)
EP (2) EP3848376A1 (cg-RX-API-DMAC7.html)
JP (3) JP6770946B2 (cg-RX-API-DMAC7.html)
KR (2) KR20230136693A (cg-RX-API-DMAC7.html)
CN (2) CN115364061A (cg-RX-API-DMAC7.html)
AR (1) AR101286A1 (cg-RX-API-DMAC7.html)
AU (4) AU2015293539A1 (cg-RX-API-DMAC7.html)
CA (1) CA2954840A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017000180A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017000586A2 (cg-RX-API-DMAC7.html)
DK (1) DK3172209T3 (cg-RX-API-DMAC7.html)
EA (2) EA202191301A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP17011672A (cg-RX-API-DMAC7.html)
ES (1) ES2857523T3 (cg-RX-API-DMAC7.html)
FR (1) FR22C1058I2 (cg-RX-API-DMAC7.html)
GT (1) GT201700007A (cg-RX-API-DMAC7.html)
HU (2) HUE053346T2 (cg-RX-API-DMAC7.html)
IL (1) IL250166B (cg-RX-API-DMAC7.html)
JO (1) JO3618B1 (cg-RX-API-DMAC7.html)
MX (2) MX379279B (cg-RX-API-DMAC7.html)
MY (1) MY187276A (cg-RX-API-DMAC7.html)
NL (1) NL301208I2 (cg-RX-API-DMAC7.html)
NO (1) NO2022058I1 (cg-RX-API-DMAC7.html)
PE (1) PE20170523A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017500121A1 (cg-RX-API-DMAC7.html)
PL (1) PL3172209T3 (cg-RX-API-DMAC7.html)
PT (1) PT3172209T (cg-RX-API-DMAC7.html)
SG (2) SG10201900648SA (cg-RX-API-DMAC7.html)
SI (1) SI3172209T1 (cg-RX-API-DMAC7.html)
TW (2) TWI724993B (cg-RX-API-DMAC7.html)
WO (1) WO2016012963A1 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX371119B (es) 2012-04-03 2020-01-17 Novartis Ag Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
SG10201900648SA (en) 2014-07-25 2019-02-27 Novartis Ag Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
CN109789141B (zh) 2016-08-10 2022-08-26 豪夫迈·罗氏有限公司 包含Akt蛋白激酶抑制剂的药物组合物
TW202444706A (zh) 2019-05-16 2024-11-16 瑞士商諾華公司 N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀
CA3155373A1 (en) * 2019-10-24 2021-04-29 Young Il Kim A pharmaceutical preparation comprising an amide derivative inhibiting the growth of cancer cell and a pharmaceutical product containing the same
WO2022007752A1 (zh) * 2020-07-06 2022-01-13 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物及其二盐酸盐的新晶型及其制备方法
CN114853762B (zh) * 2021-02-03 2026-03-06 四川科伦药物研究院有限公司 一种咪唑并三嗪类化合物的固体形式及其制备方法和用途
WO2023138492A1 (zh) * 2022-01-19 2023-07-27 南京明德新药研发有限公司 一种包含嘧啶基团的三并环类化合物的组合物及其制备方法和应用
WO2023249994A1 (en) * 2022-06-22 2023-12-28 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
IL318882A (en) * 2022-08-19 2025-04-01 Mirati Therapeutics Inc Solid pharmaceutical preparations of Adagrasib
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6762778B1 (en) 1999-06-10 2004-07-13 Dassault Systemes Three dimensional graphical manipulator
CA2465565A1 (en) 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
CA2615063A1 (en) 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
ES2393117T3 (es) 2005-09-12 2012-12-18 Actelion Pharmaceuticals Ltd. Composición farmacéutica estable que comprende una pirimidina-sulfamida
CA2563690C (en) * 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
GEP20125658B (en) 2006-11-22 2012-10-10 Incyte Corp Imidazotriazines and imidazo pyrimidines as kinase inhibitors
SI2300455T1 (sl) 2008-05-21 2017-12-29 Incyte Holdings Corporation Soli 2-fluoro-n-metil-4-(7-(kinolin-6-il-metil)-imidazo(1,2-b)1,2,4) triazin-2-il)benzamid in postopki v zvezi z njihovo pripravo
EP3566697B1 (en) * 2009-11-09 2024-09-11 Wyeth LLC Tablet formulations of neratinib maleate
IL309564A (en) 2010-02-25 2024-02-01 Pfizer Preparations containing apixaban
EA202091303A3 (ru) * 2010-05-21 2021-05-31 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
CA2804506C (en) 2010-07-06 2018-08-21 Janssen Pharmaceutica Nv Formulation for co-therapy treatment of diabetes
CA2879704A1 (en) 2012-08-16 2014-02-20 Novartis Ag Combination of pi3k inhibitor and c-met inhibitor
SG10201900648SA (en) 2014-07-25 2019-02-27 Novartis Ag Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide

Similar Documents

Publication Publication Date Title
JP7002587B2 (ja) 2-フルオロ-n-メチル-4-[7-(キノリン-6-イルメチル)イミダゾ[1,2-b][1,2,4]トリアジン-2-イル]ベンズアミドの錠剤
RU2017134002A (ru) Стабильные композиции тетрагидробиоптерина
JP2007091758A5 (cg-RX-API-DMAC7.html)
HRP20160654T1 (hr) 1-(3,3-DIMETILBUTIL)-3-(2-FLUOR-4-METIL-5-(7-METIL-2-(METILAMINO)PIRIDO[2,3-d]PIRIMIDIN-6-IL)FENIL)UREA KAO INHIBITOR Raf KINAZE U LIJEČENJU RAKA
JP2012520861A5 (cg-RX-API-DMAC7.html)
JP2015518885A5 (cg-RX-API-DMAC7.html)
CA2687741A1 (en) Stabilized amorphous forms of imatinib mesylate
JP2008517913A5 (cg-RX-API-DMAC7.html)
SI2729130T1 (en) Combined formulations of darunavir
JP2018534314A5 (cg-RX-API-DMAC7.html)
JP2007523210A5 (cg-RX-API-DMAC7.html)
KR20190014536A (ko) 3종의 항바이러스 화합물의 조합 제제
WO2014154643A1 (en) Extended release formulations of metformin
JP2013526579A5 (cg-RX-API-DMAC7.html)
JP2013511525A5 (cg-RX-API-DMAC7.html)
JP6216408B2 (ja) 固体剤形で非常に難溶性の薬物を調製する方法
JP2016508995A5 (cg-RX-API-DMAC7.html)
FI3389638T3 (fi) Pimobendaania käsittävä lääkekoostumus
JP2018528238A5 (cg-RX-API-DMAC7.html)
JP2020090484A (ja) エルロチニブを有効成分とする医薬錠剤
HK40049437A (en) Tablet formulation of a c-met inhibitor
CN114364386A (zh) 一种抗肿瘤药物组合物以及提高化合物的溶解度的方法
JP2017078053A (ja) フェキソフェナジン塩酸塩の錠剤。
JP2017507963A5 (cg-RX-API-DMAC7.html)